(IN BRIEF) Sanofi’s Dupixent has been granted FDA priority review for the treatment of bullous pemphigoid (BP), a chronic skin disease. If approved, Dupixent would be the first targeted medicine for BP in the U.S., with the FDA’s decision expected … Read the full press release →
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged bullous pemphigoid, chronic conditions, clinical trial, corticosteroid, disease remission, Dupixent, Dupixent sBLA, FDA approval, FDA priority review, orphan drug designation, regulatory news, Sanofi, skin disease, targeted treatment